Compare BFS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | CDNA |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.9M | 1.0B |
| IPO Year | N/A | 2007 |
| Metric | BFS | CDNA |
|---|---|---|
| Price | $33.54 | $17.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $27.33 |
| AVG Volume (30 Days) | 55.0K | ★ 534.7K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $6.07 | $15.37 |
| Revenue Next Year | $7.05 | $11.23 |
| P/E Ratio | $30.48 | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $29.16 | $10.96 |
| 52 Week High | $36.51 | $21.49 |
| Indicator | BFS | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 43.92 |
| Support Level | $32.53 | $16.62 |
| Resistance Level | $35.18 | $18.02 |
| Average True Range (ATR) | 0.88 | 0.69 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 32.43 | 43.79 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.